Search PRCT
PROCEPT BioRobotics Corp
Nasdaq · CIK 1588978
Last close17.16
Daily change+0.14 (0.82%)
10 Years gain-59.08%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PRCT · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
65.9Momentum
100.0Acceleration
90.3Confidence
91.0Annual Revenue6
Quarterly Revenue18
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality20.3 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.6 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 4.2552 percentage points.
Operating leverageOperating margin improved by 15.3064 percentage points.
ROIC expansionROIC improved by 5.1539 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM50.89%OK
Revenue CAGR 3Y60.14%OK
Gross Margin65.29%OK
Operating Margin-30.98%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-27.54%OK
Incremental Operating Margin 3Y-15.68%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.92%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $308.05M | $196.23M | -$103.86M | -$48.99M | -$58.34M | 63.7% | -33.71% | -18.94% | -65.39% | 55.54M |
| 2025 FY Dec 31, 2024 | $224.50M | $137.10M | -$96.61M | -$99.21M | -$103.62M | 61.07% | -43.04% | -46.16% | -78.35% | 52.13M |
| 2025 FY Dec 31, 2023 | $136.19M | $71.05M | -$109.17M | -$108.00M | -$133.21M | 52.17% | -80.16% | -97.81% | n/a | 47.26M |
| 2024 FY Dec 31, 2022 | $75.01M | $37.09M | -$80.72M | -$80.38M | -$83.04M | 49.44% | -107.61% | -110.69% | n/a | 44.4M |
| 2023 FY Dec 31, 2021 | $34.47M | $15.87M | -$54.16M | -$57.33M | -$57.93M | 46.02% | -157.12% | -168.03% | n/a | 16.48M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $340.14M | sum latest 4 fiscal quarters Revenue | OK | 0001588978-26-000030, 0001588978-25-000051 |
| Revenue Growth TTM | 50.89% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001588978-26-000030, 0001588978-25-000051 |
| Revenue CAGR 3Y | 60.14% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001588978-26-000009 |
| Revenue CAGR 5Y | 109.04% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001588978-26-000009 |
| Gross Profit CAGR 3Y | 74.26% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001588978-26-000009 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001588978-26-000030, 0001588978-25-000051 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 65.29% | Gross Profit / Revenue | OK | 0001588978-26-000030, 0001588978-25-000051 |
| Operating Margin | -30.98% | Operating Income / Revenue | OK | 0001588978-26-000030, 0001588978-25-000051 |
| ROIC | -27.54% | NOPAT / Average Invested Capital | OK | 0001588978-26-000030, 0001588978-25-000051 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001588978-26-000030 |
| Current Ratio | 6.55x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 4.41x | (Cash + Short-term Investments) / Total Debt | OK | 0001588978-26-000030 |
| Revenue per Diluted Share | $5.96 | Revenue / Diluted Shares | OK | 0001588978-26-000030, 0001588978-25-000051 |